Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 7, 2005
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the NewsMakers in the Biotech...
-
Aug 23, 2005
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jeffrey Cooper has been promoted to the position of Chief Financial Officer, effective immediately. Mr. Cooper succeeds...
-
Aug 1, 2005Conference Call and Webcast to Be Held Tuesday, August 2, at 12:00 p.m. EDT (18:00 CEST)
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced results for its second quarter ended June 30, 2005. The net loss was $21.3 million ($0.33 per share) for the second quarter of...
-
Aug 1, 2005
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for Orapred ODT(TM) (prednisolone sodium...
-
Jul 14, 2005$59.9 Million of Common Stock Priced
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that it plans to publicly offer 8,500,000 shares of its common stock, pursuant to an effective shelf registration statement. In...
-
Jul 5, 2005- New Top Line 2005 Product Revenue Guidance Issued -
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has eliminated 58 positions, of which 52 were held by personnel responsible for the sale of Orapred(R) (prednisolone...
-
Jun 21, 2005
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has appointed Stephen Aselage to the position of Senior Vice President, Global Commercial Operations, effective July 1,...
-
Jun 21, 2005
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Naglazyme(TM) (galsulfase) is now available in the United States as the first specific therapy approved for the treatment...
-
Jun 13, 2005
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer and Director of BioMarin, will present a company update at the Morgan...
-
May 31, 2005
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has entered into a settlement agreement with OrbiMed Advisors and its affiliated funds with respect to the election of...
-
May 31, 2005First Specific Therapy Approved for the Treatment of MPS VI
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Naglazyme(TM) (galsulfase), the first...
-
May 16, 2005Call to be Broadcast Live Over the Internet
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that the company will host a conference call today, Monday, May 16, 2005, at 12:00 p.m. EDT (18:00 CEST), to discuss recent...
-
May 15, 2005Phenoptin Currently in Phase 3 Trials
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Serono (virt-x: SEO and NYSE: SRA) announced today that they have formed a strategic alliance for the further development and...
-
May 11, 2005
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that its board of directors has elected Jean-Jacques Bienaime as the company's Chief Executive Officer, effective immediately,...
-
May 5, 2005Conference Call and Webcast to Be Held Monday, May 16, at 12:00 PM EDT (18:00 CEST)
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced results for its first quarter ended March 31, 2005. The net loss was $22.5 million ($0.35 per share) for the first quarter of...
-
May 4, 2005
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has licensed from Daiichi Suntory Pharma Co., Ltd. the exclusive worldwide rights (excluding Japan) for the use of...
-
Apr 6, 2005
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has randomized the first patient in its Phase 3 clinical trial of Phenoptin(TM) (sapropterin hydrochloride), an...
-
Mar 8, 2005Further Improvements in Patients Receiving rhASB and Significant Improvements in Patients Previously Receiving Placebo
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced positive results from the Phase 3 extension study of rhASB (galsulfase), the company's investigational enzyme replacement...
-
Feb 22, 2005Conference Call and Webcast to be Held Today at 12:00 PM ET (18:00 CET)
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced results for its fourth quarter and year ended December 31, 2004. The net loss was $82.4 million ($1.28 per share) for the fourth...
-
Jan 31, 2005PDUFA Date Set for May 31, 2005
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and assigned six-month review to the Biologics License...
-
Jan 25, 2005
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced preliminary unaudited fourth quarter and year-end 2004 net sales for Orapred(R) (prednisolone sodium phosphate oral solution)...
-
Dec 22, 2004
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that it has initiated its Phase 2 clinical trial of Phenoptin(TM) (sapropterin hydrochloride), an investigational oral, small...
-
Dec 5, 2004
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency for Aryplase(TM)...
-
Nov 29, 2004Blood Phenylalanine Level will be the Primary Efficacy Measurement
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it expects to initiate a six-week, multi-center, international, double-blind, placebo-controlled Phase 3 clinical trial of...
-
Nov 28, 2004
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Aryplase(TM)...
-
Nov 22, 2004Partnership Enables BioMarin to Accelerate Phenoptin Program
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has entered into a strategic business partnership with Daiichi Suntory Pharma Co., Ltd., for Phenoptin(TM) (sapropterin...
-
Nov 2, 2004Conference Call and Webcast to be Held Today at 12:00 PM EST (18:00 CET)
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for the third quarter of the fiscal year 2004. The company incurred a net loss of $29.5 million ($0.46 per...
-
Sep 21, 2004Excess Orapred Inventory in Distribution Channel Likely to Cause Temporary Revenue Shortfall
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has revised its financial guidance based on reduced 2004 revenue expectations for Orapred(R), the company's product for...
-
Sep 21, 2004Event to Take Place Saturday, October 2, at the Marin Center Lagoon Park in San Rafael, California
BioMarin Pharmaceutical Inc. announced today that the second annual BioMarin/MPS "Run for Your Life" 5K Run/Walk will take place on Saturday, October 2, 2004, at the Marin Center Lagoon Park...
-
Aug 24, 2004
BioMarin Pharmaceutical Inc. today announced positive results from a Phase 1b clinical trial of Vibrilase(TM) (vibriolysin), an investigational topical enzyme for the treatment of serious burns....
-
Aug 23, 2004Application Includes Extensive Preclinical and Clinical Data on 6R-BH4
BioMarin Pharmaceutical Inc. announced that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for Phenoptin(TM), BioMarin's proprietary...
-
Aug 12, 2004
BioMarin Pharmaceutical Inc. announced today that Fredric D. Price has resigned as Chairman and Chief Executive Officer (CEO) of the company in order to relocate back to the East Coast. Pierre...
-
Aug 9, 2004Second Quarter GAAP Net Loss of $0.86 Per Share and Pro Forma Adjusted Net Loss of $0.28 Per Share
BioMarin Pharmaceutical Inc. today announced financial results for the second quarter of the fiscal year 2004. The company incurred a GAAP net loss of $55.6 million ($0.86 per share) for the...
-
Jul 19, 2004Study Demonstrates Substantial Reduction in Phenylalanine Levels in PKU Patients
BioMarin Pharmaceutical Inc. announced positive results from a pilot clinical study of 6R-BH4 in 20 patients with phenylketonuria (PKU). 6R-BH4 is the active agent in Phenoptin(TM), an...
-
Jun 2, 2004Aryplase Demonstrates Statistically Significant Benefit in Primary Endpoint
BioMarin Pharmaceutical Inc. today announced positive results from its Phase 3 clinical trial of Aryplase(TM), an investigational enzyme replacement therapy for the treatment of...
-
May 18, 2004
BioMarin Pharmaceutical Inc. announced that it has completed the transaction, announced April 20, 2004, to obtain Ascent Pediatrics, a profitable pediatrics business that includes Orapred(R), the...
-
May 3, 2004Conference Call and Webcast to be Held Today at 12:00 p.m. EDT (18:00 CEST)
BioMarin Pharmaceutical Inc. today announced financial results for the first quarter of the fiscal year 2004. The company incurred a net loss of $19.9 million ($0.31 per share) for the quarter...
-
Apr 20, 2004Ascent Pediatrics, Inc. Provides BioMarin with Growing Product Revenues and Commercial Infrastructure to Launch its Pipeline of Pediatric Products
BioMarin Pharmaceutical Inc. today announced that it has signed definitive agreements with Medicis Pharmaceutical Corporation to obtain its Pediatric Business as defined in the transaction...
-
Dec 29, 2003
Patients receiving protein-based biopharmaceuticals may eventually benefit from a technology to improve their immune tolerance to such treatments, according to early stage research to be published...
-
Nov 19, 2003BioMarin Accelerates Development of Phenoptin, a Novel Oral Enzyme Cofactor for the Treatment of PKUIf Approved, Phenoptin Could Become the First Prescription Drug for the Treatment of PKU
BioMarin Pharmaceutical Inc. announced plans to begin clinical trials with Phenoptin(TM), an enzyme cofactor that is a second generation, proprietary oral form of tetrahydrobiopterin, for the...
-
Nov 5, 2003BioMarin on Track to File for US and EU Marketing Authorization in 2004 Pending Positive Results from the Ongoing Phase 3 Study
BioMarin Pharmaceutical Inc. announced positive long-term results from Phase 1 and Phase 2 clinical studies of Aryplase(TM), an investigational enzyme replacement therapy for the treatment of...
-
Nov 3, 2003Conference Call and Webcast to be Held Today at 12:00 PM ET (18:00 CET)
BioMarin Pharmaceutical Inc. today announced financial results for its third quarter ended September 30, 2003. The net loss was $21.3 million ($0.33 per share) for the third quarter of 2003...
-
Sep 21, 2003BioMarin Spending Projected to Decrease in Both 2003 and 2004
BioMarin Pharmaceutical Inc. announced that it halted its Phase 3a study of Neutralase(TM) for the reversal of anticoagulation by heparin in primary Coronary Artery Bypass Graft (CABG) surgery and...
-
Sep 3, 2003Data Warrants Further Study of Intrathecal Injection of Enzyme for Treating Neurological Symptoms of MPS I
BioMarin Pharmaceutical Inc. announced results from studies indicating that intrathecal injection of recombinant human alpha-L-iduronidase (rhIDU) can reduce carbohydrate storage in brain tissue...